Journal articles on the topic 'Ulcerative colitise'
To see the other types of publications on this topic, follow the link: Ulcerative colitise.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Ulcerative colitise.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Costa, Gabrielle Azevêdo, Giovanna Souza Carvalho, Lenzzy Coelho Pereira, Stephanie Gesteira Vilas Boas Sena Costa, and Cristina Aires Brasil. "Epidemiological Profile of Patients with Crohn's Disease and Ulcerative Colitis in the Last 6 Years." Journal of Health Sciences 24, no. 1 (March 22, 2022): 63–66. http://dx.doi.org/10.17921/2447-8938.2022v24n1p63-66.
Abstract:
Abstract Inflammatory bowel diseases, Crohn's Disease and Ulcerative Colitis, are two relevant changes in the intestinal microbiota of individuals who are subject to environmental and genetic changes. With the social development and, mainly, the spread of industrialization, the increase in gastrointestinal diseases was observed on a large scale. Therefore, the study permeated to relate and obtain its results according to ethnicity, sex, phenotypic alterations of PID and gender, which are risk factors for these diseases. To characterize the epidemiological profile of patients with Crohn's Disease and Ulcerative Colitis in Brazil in the last 6 years. This is a time series epidemiological study with the objective of collecting data from patients who were diagnosed with Crohn's Disease and Ulcerative Colitis, in all Brazilian regions from 2014 to 2019. Data will be collected in the System of SUS Hospital Information (SIH/SUS), within a period of 6 years and for the analysis of these data, sociodemographic variables will be used, namely: ethnicity, sex, region, age group and admissions number, being accessed on 09/22/2020. The panorama presented shows high rates of hospitalization in the Southeast and Northeast regions, the diagnosis for the two diseases predominate in the South region, females, ethnicity/white race and age group between 20 and 29 years highlighted. Thus, the intervention of public policies that improve the population's health condition is of paramount importance. Keywords: Hospitalization. Epidemiology. Inflammatory Bowel Diseases. ResumoAs doenças inflamatórias intestinais, Doença de Crohn e a Colite Ulcerativa, são duas alterações pertinentes na microbiota intestinal de indivíduos que estão sujeitos a mudanças do ambiente e genéticas. Com o desenvolvimento social e, principalmente, alastramento da industrialização o aumento das doenças gastrintestinais foi observado em larga escala. Sendo assim, o estudo permeou em relacionar e obter os seus resultados de acordo a etnia, sexo, alterações fenotípicas de IDP e gênero, que são fatores de riscos para essas doenças. O objetivo desse estudo foi caracterizar o perfil epidemiológico de pacientes com doença de Crohn e colite ulcerativa, no Brasil, nos últimos 6 anos. Trata-se de um estudo epidemiológico de serie temporal com o objetivo de coletar dados de pacientes que foram diagnosticados com doença de Crohn e colite ulcerativas, em todas as regiões brasileiras no período de 2014 até 2019. Os dados serão coletados no Sistema de Informações Hospitalares do SUS (SIH/SUS), dentro do período de 6 anos e para a análise desses dados, serão utilizadas as variáveis sociodemográficas, que são: etnia, sexo, região, faixa etária e números de internações, sendo acessado no dia 22/09/2020. O panorama apresentado demostra altas taxas de internação nas regiões sudeste e nordeste, o diagnóstico para as duas doenças predominam na região sul, o sexo feminino, etnia/raça branca e faixa etária entre 20 e 29 anos em destaque. Desta forma, é de suma importância a intervenção de políticas públicas que melhorem a condição de saúde da população. Palavras-chave: Hospitalização. Epidemiologia. Doenças Inflamatórias Intestinais.
2
Tobin, Jacinta M., Bidisa Sinha, Pramila Ramani, Abdul R. H. Saleh, and M. Stephen Murphy. "Upper Gastrointestinal Mucosal Disease in Pediatric Crohn Disease and Ulcerative Colitis: A Blinded, Controlled Study." Journal of Pediatric Gastroenterology and Nutrition 32, no. 4 (April 2001): 443–48. http://dx.doi.org/10.1002/j.1536-4801.2001.tb07295.x.
Abstract:
ABSTRACTBackgroundUpper gastrointestinal endoscopic biopsies often show histologic abnormalities in Crohn disease. Consequently, it has been proposed that routine endoscopy could help to distinguish Crohn disease from ulcerative colitis. Surprisingly, however, recent case reports and an uncontrolled study suggested that similar abnormalities may occur in ulcerative colitis. Therefore, a blinded, controlled study was performed.MethodsEsophageal, gastric antral, and duodenal biopsies from children with Crohn disease (n = 28) and ulcerative colitis (n = 14) were compared with those from controls undergoing endoscopy for suspected reflux esophagitis (n = 22). Two pathologists, unaware of patient identity and diagnosis, agreed on a consensus report. Severity of inflammation was scored semiquantitatively. Helicobacter pylori colonization was an exclusion criterion.ResultsInflammation was reported as follows: esophagitis: controls 91%; Crohn disease: 72%; ulcerative colitis: 50%; gastritis: controls: 27%; Crohn disease: 92% (P < 0.001); ulcerative colitis: 69%; duodenitis: controls: 9%; Crohn disease: 33%; ulcerative colitis: 23%. In Crohn disease, granulomas were noted in 40% of patients (P = 0.001). Duodenal cryptitis was noted in 26% of patients with Crohn disease but not ulcerative colitis. In one patient with ulcerative colitis, neutrophilic infiltration of gastric glands was seen. Abnormalities seen in Crohn disease and ulcerative colitis included gastroduodenal ulceration (Crohn disease, 7%; ulcerative colitis, 8%), villus atrophy (Crohn disease, 11%; ulcerative colitis, 15%), and increased intraepithelial lymphocytes (Crohn disease, 15%; ulcerative colitis, 31% [P < 0.05]). None of these abnormalities was noted in the controls.ConclusionAlthough the presence of granulomas can support a diagnosis of Crohn disease, severe inflammation and other abnormalities occur in the proximal gastrointestinal tract in Crohn disease and ulcerative colitis.
3
Garey, Kevin W., Daniel S. Streetman, and Michael C. Rainish. "Azathioprine Hypersensitivity Reaction in a Patient with Ulcerative Colitis." Annals of Pharmacotherapy 32, no. 4 (April 1998): 425–28. http://dx.doi.org/10.1345/aph.17395.
Abstract:
OBJECTIVE: To describe a case of azathioprine hypersensitivity in a patient with ulcerative colitis. CASE SUMMARY: A 40-year-old white man with ulcerative colitis, treated with chronic mesalamine and occasional steroids, was admitted to the hospital with a 3-day history of fever, nausea, vomiting, and a rash. Fourteen days prior to admission, the patient had been started on azathioprine for ulcerative colitis. Upon admission, azathioprine therapy was temporarily withheld, resulting in resolution of his signs and symptoms. Symptoms returned when azathioprine was restarted. It was decided that these signs and symptoms were most likely caused by azathioprine hypersensitivity, and the agent was discontinued. DISCUSSION: To our knowledge, this is the first reported case of azathioprine hypersensitivity in a patient with ulcerative colitis. The time course and presenting signs and symptoms support the diagnosis of azathioprine hypersensitivity, as does the patient's response to rechallenge. The mechanism of this hypersensitivity reaction is unclear, but may involve the nitroimidazole portion of the azathioprine molecule. CONCLUSIONS: Azathioprine hypersensitivity often presents with signs and symptoms resembling a systemic infection such as fever, leukocytosis, and evidence of end organ dysfunction. The diagnosis of azathioprine hypersensitivity should be considered in patients who have recently either initiated or increased their dosage of azathioprine. OBJETIVO: Reportar un caso de hipersensitividad a azathioprine en un paciente con colitis ulcerativa. RESUMEN DEL CASO: Un hombre de 40 años con colitis ulcerativa tratado cronicamente con mesalamine y ocasionalmente esteroides, fue hospitalizado con un historial de 3 días con fiebre, naúsea, vómitos, e irritación en la piel. Catorce días previo a la admisión, el paciente había comenzado en azathioprine para su colitis ulcerativa. En la admisión, la azathioprine fue temporalmento descontinuada resultando en la resolución de los signos y síntomas. Los síntomas comenzaron cuando se utilizó nuevamente el azathioprine. Se decidió que estos signos y síntomas eran bien parecidos a una hipersensitividad a azathioprine y el medicamento fue descontinuado. DISCUSIÓN: Hasta donde se conoce es el primer caso reportado con hipersensitividad a azathioprine en un paciente con colitis ulcerativa. El tiempo del curso y presentación de los signos y síntomas apoyan el hallazgo así como la respuesta del paciente al ser tratado nuevamente. El mecanismo de esta hipersensitividad no está claro pero podría envolver la porción de nitromidazole de la mólecula de azathioprine. CONCLUSIONES: A menudo la hipersensitividad a azathioprine presenta los signos y síntomas parecidos en una infección sistémica como fiebre, leucosiotosis, y evidencia de disfunción en órganos terminales. El diagnóstico de hipersensitividad a azathioprine debe ser considerado en pacientes que recientemente comenzaron en el medicamento y en casos en que se les aumente la dosis de azathioprine. OBJECTIF: Rapporter un cas d'hypersensibilité à l'azathioprine chez un patient atteint de colite ulcéreuse. RÉSUMÉ DU CAS: Un homme de 40 ans attéint de colite ulcéreuse et traité de façon chronique avec de la mésalamine et occasionnellement avec des corticostéroïdes a été admis à l'hôpital pour fièvre, nausées, vomissements, et rash persistant depuis 3 jours. Quatorze jours avant son admission, un traitement à l'azathioprine avait été débuté pour sa colite ulcéreuse. À l'admission, l'azathioprine a été temporairement cessée, ce qui a permis la résolution des signes et symptômes. Les symptômes sont réapparus lorsque l'azathioprine a été reprise. Les signes et symptômes présentes par le patient étant compatibles avec une réaction d'hypersensibilité à l'azathioprine, il fut décidé de cesser définitivement l'azathioprine. DISCUSSION: Selon les auteurs, il s'agirait du premier cas d'hypersensibilité à l'azathioprine rapporté chez un patient atteint de colite ulcéreuse. l'évolution de la réaction dans le temps, les signes et symptômes de même que la réapparition des symptômes lors de la réadministration du médicament tendent à incriminer l'azathioprine. Le mécanisme de cette réaction d'hypersensibilité n'est pas clairement défini mais pourrait impliquer la portion nitroimidazole de la molécule d'azathioprine. CONCLUSIONS: L'hypersensibilité à l'azathioprine se manifeste fréquemment par des signes et symptômes ressemblant à une infection systémique tels que fièvre, leucocytose, et évidence de dysfonction d'un organe. Le diagnostic d'hypersensibilité à l'azathioprine devrait être considéré chez les patients qui reçoivent depuis peu de l'azathioprine ou chez qui la dose d'azathioprine a été augmentée.
4
Silvia Pop, Corina, Roxana Maria Nemes, and George Pariza. "Surgical Approaches in Fulminant Ulcerative Colitis." Global Journal For Research Analysis 3, no. 5 (June 15, 2012): 115–17. http://dx.doi.org/10.15373/22778160/may2014/43.
5
Tomasik, Mikołaj, Paweł Warzyszak, Róża Małek, Maria Milczek, Wojciech Żołyniak, Izabela Hawranik, Szymon Niski, Ziemowit Żaba, Aleksandra Lisowska, and Mateusz Skrzypek. "Ulcerative colitis – recent and potential methods of treatment - review." Journal of Education, Health and Sport 13, no. 3 (January 17, 2023): 65–73. http://dx.doi.org/10.12775/jehs.2023.13.03.009.
Abstract:
Introduction and purpose: Ulcerative colitis (UC, colitis ulcerosa) belongs to a group of inflammatory bowel diseases of unexplained etiology. It is a diffuse nonspecific inflammation of the mucosa of the rectum or rectum and colon, leading to ulceration in more severe cases. Despite a decline in the incidence of ulcerative colitis in developed countries, the prevalence continues to rise due to increasingly predominant benign course of the disease with a low mortality rate. The purpose of this review is to summarize latest directions and discoveries in research of ulcerative colitis. Materials and methods: This review is based on articles published in Pubmed between 2017 and 2022 by searching keywords ulcerative colitis treatment, ulcerative colitis guidelines.State of knowledge: Currently, many independent scientific societies represent a consensus position on the standard management of patients with UC, while recent therapeutic options are constantly emerging due to intensive research. These options require the involvement of multiple medical centers to determine their position in future guidelines.Conclusion: Although ulcerative colitis is a disease that is diagnosed and detected relatively easily, due to its chronic nature, relatively high prevalence in the population and lack of causal treatment options, it is an important direction for further research.
6
Arellano, Nelson Darío, and Larissa Inés Páez. "Colectomy for severe ulcerative colitis." Anales de la Facultad de Ciencias Médicas (Asunción) 54, no. 2 (August 30, 2021): 151–56. http://dx.doi.org/10.18004/anales/2021.054.02.151.
7
Soni, Dr Aakanksha. "Evaluation of the Factors Associated with Post-Operative Outcome in Patients of Ulcerative Colitis Undergoing Ileal Pouchanal Anastomosis with Comparison of Functional Outcome between Stapler and Hand-Sewn Anastomosis." Journal of Medical Science and clinical Research 12, no. 01 (January 31, 2024): 11–19. http://dx.doi.org/10.18535/jmscr/v12i01.03.
Abstract:
ntroduction Ulcerative colitis defined as a non-granulomatous idiopathic inflammatory disease which mainly affects the colon and rectum. The disease may arise at any age but most commonly affects the adults between the age group of 30–40 years.1,2. The etiology of the disease is multifactorial, involving genetic predisposition, dysregulated immune responses, epithelial barrier defects and environmental factors. No sex predilection is seen in ulcerative colitis.3,5 The peak age of onset of disease is between 30 to 40 years.4,6 The environmental factors has also been found to play an important role in the etiopathogenesis of ulcerative colitis. Cigarette smoking is one of the major factor associated with ulcerative colitis, non-smokers have a milder disease course and active smokers are less likely to develop ulcerative colitis7 Appendectomy also confers a protective effect against ulcerative colitis, especially in young patients operated for acute appendicitis.8. Classic findings in endoscopy in patients with ulcerative colitis include loss of normal vascular pattern, erythema, erosions, granularity, friability, ulcerations and bleeding9 . The primary aim of medical management is to induce and maintain remission with the long-term goals of improving quality of life and prevent disability. Absolute indications for surgery include uncontrolled hemorrhage, perforation, and colorectal carcinoma or dysplastic lesions not amenable to endoscopic removal.10 Surgery is also indicated in refractory acute severe ulcerative colitis or medically refractory disease. The most commonly performed surgery for ulcerative colitis is restorative proctocolectomy with ileal pouchanal anastomosis (IPAA). An important aspect of the surgery is the use of either sutures or staplers for anastomosis. Two types of ileal pouch-anal anastomosis (IPAA) have been described: a mucosectomy of the rectal stump followed by a hand-sewn ileal pouch-anal anastomosis.11 The alternative technique is to retain the mucosa of the rectal stump and perform a stapled pouch-anal anastomosis.
8
Jaeger, Karine Nava, Maria Eduarda Mintzfels Branco, Ileana Simone de Oliveira Moura, Lorenzo Gabriel de Azevedo Viera, Jhoni Michael de Oliveira Cardoso, Caroline Bezerra Trajano dos Santos, Carlos Galvão Branco Araújo, et al. "Segurança do Vedolizumabe no tratamento da Retocolite Ulcerativa: Uma revisão de literatura." Brazilian Journal of Implantology and Health Sciences 6, no. 1 (January 26, 2024): 1918–26. http://dx.doi.org/10.36557/2674-8169.2024v6n1p1918-1926.
Abstract:
A colite ulcerativa pertence ao grupo de doenças inflamatórias intestinais, que representam patologias influenciadas por fatores genéticos e ambientais, resultando em um desequilíbrio imunológico seguido de lesões teciduais. Essas provocações ambientais desencadeiam processos inflamatórios restritos à camada mucosa do cólon, em especial no reto, podendo avançar para outras regiões. As principais intervenções terapêuticas são o manejo cirúrgico e o uso de medicamentos, como o Vedolizumabe. Este artigo tem por objetivo realizar uma varredura da literatura médica vigente sobre o tratamento da Retocolite Ulcerativa utilizando o Vedolizumabe. Trata-se de uma revisão integrativa da literatura, utilizando as bases de dados Pubmed e Biblioteca Virtual de Saúde (BVS), por meio do cruzamento dos descritores “vedolizumab”, “therapeutic” e “ulcerative colitis”, com operador booleano “AND”. As buscas resultam em 509 artigos, sendo selecionados os que coincidem com a temática em foco e excluídos o restante pela menor abrangência e fuga do tema. Dentre os critérios de inclusão, foram inseridos artigos em português, inglês e espanhol, em especial dos últimos 5 anos, resultando em 6 artigos. O fármaco Vedolizumabe possui propriedades imunossupressoras específicas ao intestino, demonstrando indicação para o tratamento da colite ulcerativa moderada a grave. Esse medicamento, apresenta ação através da sua ligação à integrina α4β7 expressa em linfócitos T intestinais, inibindo o processo inflamatório e diminuindo a sintomatologia do paciente. Assim, medidas terapêuticas por meio desse fármaco, destinada a pacientes com retocolite ulcerativa, mostra-se segura e eficaz.
9
Proujansky, Roy, Paul T. Fawcett, Kathleen M. Gibney, William R. Treem, and Jeffrey S. Hyams. "Examination of Anti‐Neutrophil Cytoplasmic Antibodies in Childhood Inflammatory Bowel Disease." Journal of Pediatric Gastroenterology and Nutrition 17, no. 2 (August 1993): 193–97. http://dx.doi.org/10.1002/j.1536-4801.1993.tb10946.x.
Abstract:
SummaryThe detection of anti‐neutrophil cytoplasmic antibodies (ANCA), in a perinuclear fluorescence pattern, in the serum of adults with inflammatory bowel disease has recently been described to be sensitive and specific for a diagnosis of ulcerative colitis in comparison to Crohn's disease and other colitides. We have examined the sera of 41 children and adolescents with ulcerative colitis, 27 with Crohn's disease, and a control group for the presence of ANCA. Anti‐neutrophil cytoplasmic antibodies were detected in the serum of 27 of 41 patients with ulcerative colitis (66%), five of 27 with Crohn's disease (19%), and in none of our control subjects or patients with functional abdominal pain. Overall, the presence of ANCA was 66% sensitive and 84% specific for a diagnosis of ulcerative colitis when compared to Crohn's disease. There was no relationship between a positive ANCA value and disease activity or other clinical indicators. We conclude that evaluation for the presence of ANCA may be a useful adjunct for the clinical assessment of patients with inflammatory bowel disease. The presence of ANCA in children and adolescents, however, will not definitively distinguish between patients with ulcerative colitis and Crohn's disease.
10
Lakatos, László, and Péter László Lakatos. "Medical therapy of inflammatory bowel diseases: Ulcerative colitis." Orvosi Hetilap 148, no. 25 (June 1, 2007): 1163–70. http://dx.doi.org/10.1556/oh.2007.28063.
Abstract:
A colitis ulcerosa kezelésében kevesebb a változás, mint a Crohn-betegségben. A betegek nagy többsége ma is a hagyományos gyógyszereket kapja. A kezelést meghatározó legfontosabb tényezők a betegség kiterjedése és súlyossága. Az enyhe és középsúlyos colitis ulcerosa kezelésének a legfontosabb szerei az aminoszalicilátok. Az új 5-aminoszalicilátok terápiás hatékonysága nem jobb, mint a sulfasalaziné, de kevesebb mellékhatásuk miatt előtérbe került az alkalmazásuk. Proctitisben és distalis colitisben a helyileg alkalmazott készítmények hatásosabbak, mint az orális szerek, de a kiterjedt colitis gyógyulását is javítja a kombinált lokális és orális kezelés. A súlyos, akut colitis ulcerosa kezelésében továbbra is meghatározóak a kortikoszteroidok, a nem reagáló esetekben a cyclosporin vagy az infliximab lehet a colectomia alternatívája. Colitis ulcerosában csaknem minden esetben indokolt a fenntartó kezelés. Valamennyi aminoszalicilát alkalmas a remisszió fenntartására. Továbbra sem tisztázott az optimális aminoszalicilát-dózis kérdése. A distalis colitis remisszióban tartásában leghatékonyabbak a lokális szerek, amennyiben a beteg ezt a kezelést elfogadja. Krónikusan aktív, szteroidra rezisztens vagy szteroidfüggő betegségben immunszuppresszív szerektől, elsősorban azathioprintól várhatunk eredményt. Az utóbbi évek felmérései szerint colitis ulcerosában az azathioprin legalább olyan hatékony, mint Crohn-betegségben. A fenntartó kezelésben fontos szempont a kemoprevenció. Mind több adat bizonyítja, hogy az aminoszalicilátok csökkentik a colitis ulcerosában fokozott colorectalis rák kialakulásának kockázatát. A legfontosabb változások a colitis ulcerosa kezelésében az utóbbi években a lokális aminoszalicilátok és az azathioprin előtérbe kerülése, az infliximab alkalmazása súlyos colitisben, valamint a karcinóma-kemoprevenció általánossá válása. Nagyobb figyelmet kell fordítani a beteg együttműködésének a megnyerésére, az előírások betartására.
11
Amatullah, Afifah, and Saptino Miro. "Pankolitis Akibat Kolitis Ulseratif." Health and Medical Journal 3, no. 2 (July 1, 2021): 43–50. http://dx.doi.org/10.33854/heme.v3i2.653.
Abstract:
Introduction: Ulcerative colitis is a chronic disease affecting large intestine, characterized by rectal bleeding, diarrhea, abdominal pain, and could be accompanied by extraintestinal manifestation such as fever, anemia, and weight loss. Ulcerative colitis is causing an inflammation even ulceration of the rectum which can extend to proximal colon. The incidence of this disease is increasing worldwide and its frequency is variable depend on age, race and geographic area. Thorough history and examination are needed in diagnosing ulcerative colitis, since its symptoms are similar to many other gastrointestinal diseases. Definitive diagnosis of ulcerative colitis can be obtained by colonoscopy and histopathology. Case Report: We reported a case of 53 years old man who suffered from diarrhea and weight loss for one month before admission. There were also blood and mucus in his stool. The result of colonoscopy was hyperemia and ulcers along the rectum to the caecum. Histopathology examination showed pieces of intestinal mucosal tissue covered by columnar epithelium, with goblet cell and round-oval core. The lamina propria is densely packed with lymphocyte cells, plasma cells and PMN leukocytes. This result represents chronic colitis with acute exacerbation. Conclusion: Patient was treated with mesalazine 3x1000 mg per oral, methyl prednisolone 3x16 mg per oral, and low fiber diet to achieve remission.
12
Wang, Y., Y. Gu, K. Fang, K. Mao, J. Dou, H. Fan, C. Zhou, and H. Wang. "Lactobacillus acidophilus and Clostridium butyricum ameliorate colitis in murine by strengthening the gut barrier function and decreasing inflammatory factors." Beneficial Microbes 9, no. 5 (September 18, 2018): 775–87. http://dx.doi.org/10.3920/bm2017.0035.
Abstract:
Ulcerative colitis is a type of chronic inflammation present in the intestines for which the aetiology is not yet clear. The current therapies for ulcerative colitis cannot be considered to be long-term management strategies due to their significant side effects. Therefore, it is essential to identify an alternative therapeutic strategy for ulcerative colitis. The present study focused on the evaluation of the anti-inflammatory activities of Lactobacillus acidophilus CGMCC 7282 and Clostridium butyricum CGMCC 7281. The roles of both single and combination of L. acidophilus CGMCC 7282 and C. butyricum CGMCC 7281 in ulcerative colitis were investigated in 2,4,6-trinitrobenzenesulfonic acid-induced acute colitis (Th1-type colitis) in Sprague-Dawley rats and oxazolone-induced chronic colitis (Th2-type colitis) in BALB/c mice. The in vivo studies showed that the administration of L. acidophilus CGMCC 7282, C. butyricum CGMCC 7281 and L. acidophilus CGMCC 7282 plus C. butyricum CGMCC 7281 could reduce the Th1-type colitis as well as the Th2-type colitis, and the combination of the two strains exhibited the most notable effects, as indicated by the reduced mortality rates, the suppressed disease activity indices, the improved body weights, the reduced colon weight/colon length and colon weight/body weight ratios, and the improved gross anatomic characteristics and histological features (ameliorations of neutrophil infiltration and ulceration in the colon). It was found that the alterations of the gut microbiome, the barrier function changing and the selected inflammation-related cytokines are observed in the ulcerative colitis rats/mice treated with L. acidophilus CGMCC 7282 and C. butyricum CGMCC 7281. The combination of L. acidophilus CGMCC 7282 plus C. butyricum CGMCC 7281 also exerted a stronger anti-inflammatory effect than either of the single strains alone in vitro. These findings provide evidence that the administration of L. acidophilus CGMCC 7282 plus C. butyricum CGMCC 7281 may be a promising therapy for ulcerative colitis.
13
Real-Delor, Raúl, Alba Aveiro, Dora Montiel, Elvira Miskinich, Alexis Benítez, and Araceli Centurión. "Colitis ulcerosa en paciente con enfermedad celiaca silente." Memorias del Instituto de Investigaciones en Ciencias de la Salud 19, no. 3 (December 1, 2021): 92–95. http://dx.doi.org/10.18004/mem.iics/1812-9528/2021.019.03.92.
Abstract:
Se presenta caso de mujer con enfermedad celiaca que presentó colitis ulcerosa complicada con megacolon tóxico. El cuadro revirtió con inmunosupresores y tratamiento médico. Se sugiere a los médicos la búsqueda activa de enfermedades autoinmunes asociadas, además del diagnóstico precoz y tratamiento oportuno de la enfermedad celiaca para evitar complicaciones.
14
Miner, PB, and WL Biddle. "Maintaining Remission in Distal Ulcerative Colitis and Ulcerative Proctitis." Canadian Journal of Gastroenterology 4, no. 7 (1990): 476–80. http://dx.doi.org/10.1155/1990/864194.
Abstract:
Maintenance of remission is an important consideration in the medical care of patients with ulcerative colitis. The relapse rate is high when medications are discontinued. Many types of medications have been investigated for potential efficacy of maintaining remission. This paper reviews the literature on maintenance therapy for both distal and universal ulcerative colitis. Sulphasalazine is the drug of choice since il is effective and relatively low m cost. 5-aminosalicylic acid (5-ASA) derivatives, both oral and rectal forms, are also effective. Other medications such as metronidazole, cromolyn sodium and prednisone have nor been shown to be effective maintenance therapy. Strategies for maintenance are outlined and include possible regimens with 5-ASA enemas. While 1 g of 5-ASA is effective, the long term relapse rate is similar co that seen with sulphasalazine. Patients capered co 1 g 5-ASA enemas have a good chance of maintaining remission if the colitis does not flare within the first few months, because most colites will flare up early on. Other possible regimens include intermittent enemas, eg, every other night or every third night. Patients in remission can be safely maintained in remission with sulphasalazine or one of its 5-ASA derivatives.
15
Dolgushina, A. I., A. A. Selyanina, E. A. Mezenceva, A. G. Vasilenko, L. I. Pozdeeva, L. Yu Zhuravleva, E. R. Olevskaya, and E. A. Fedorova. "Mycophenolate Mofetil and Clostridium difficile-associated Colitis." Russian Journal of Gastroenterology, Hepatology, Coloproctology 31, no. 4 (December 20, 2021): 64–69. http://dx.doi.org/10.22416/1382-4376-2021-31-4-64-69.
Abstract:
Aim. A clinical observation of colitis conditioned by mycophenolate mofetil intake and concomitant Clostridium difficile-associated disease.Key points. Mycophenolate mofetil (MMF) is an active immunosuppressant with side effects affecting gastrointestinal tract (GIT). A 37-yo male patient with type 1 diabetes mellitus was admitted at a gastroenterology unit with clinical signs of diarrhoea with haematochezia. A history of diabetic nephropathy and related-donor pre-dialysis kidney transplantation in 2012, since when MMF intake was 2000 mg daily. Catarrhal ulcerative colitis in colonoscopy, C. difficile toxins in pathogen stool panel. Ulcerative, ischaemic colitises and the graft-versus-host disease were ruled out in examination. A positive clinical and endoscopic trend was observed upon MMF withdrawn and start of vancomycin.Conclusion. The case presented illustrates the clinical picture and diagnostic algorithm in MMF-associated colitis. The case-distinctive is association with C. difficile infection.
16
S, Boulajaad. "Association of Ulcerative Colitis and IgA Nephropathy: A Case Report." Gastroenterology & Hepatology International Journal 6, no. 2 (July 1, 2021): 1–4. http://dx.doi.org/10.23880/ghij-16000184.
Abstract:
The extra-digestive manifestations of chronic inflammatory bowel disease most often affect the joints, skin, eyes, liver and bile ducts. Renal involvement is rare, and manifests as kidney stones, glomerulonephritis, tubulointerstitial nephritis, and AA-type secondary amyloidosis. In this context of chronic inflammatory bowel disease, in particular ulcerative colitis, renal involvement is very often secondary to nephrotoxicity of the basic treatment of digestive pathology, and very rarely an authentic extra-digestive manifestation of intestinal disease. We report a case of IgA nephropathy as an extra-digestive manifestation of ulcerative colitis.
17
Parmar, Girishkumar. "Case Study on Case of Ulcerative Colitis with Homoeopathic Medicine." International Journal of Science and Research (IJSR) 12, no. 9 (September 5, 2023): 1416–19. http://dx.doi.org/10.21275/sr23916193109.
18
Hadi, Shiva, Mahtab Farrash Bashi Masjed, Naser Shagerdi Esmaeli, and Shahin Asadi. "A Review of Colitis Ulcers in the Gastrointestinal Tract." Gastroenterology Pancreatology and Hepatobilary Disorders 5, no. 6 (October 1, 2021): 01–07. http://dx.doi.org/10.31579/2641-5194/051.
Abstract:
Colitis ulcer disease is a chronic disorder that affects the gastrointestinal tract. The disease is characterized by abnormal inflammation of the inner surface of the rectum and intestine, which makes up most of the length of the large intestine. Inflammation usually causes open sores (ulcers) in the large intestine. Doctors still do not know exactly what causes ulcerative colitis. Ulcerative colitis is an inflammatory bowel disease, but genetics appear to play an important role. Family history is seen in many patients with ulcerative colitis. In fact, having a relative with ulcerative colitis is the biggest risk factor for the disease, meaning you may inherit the genetic cause of ulcerative colitis. In addition, some environmental factors are involved in the immune system attacking the colon and developing ulcerative colitis. Families with ulcerative colitis share some of the genes that appear to be linked to the disease. Note that several genetic changes may play a role in the development of ulcerative colitis. Genes may stimulate ulcerative colitis by altering the immune system response or disrupting the protective barrier of the intestinal wall.
19
Dias, E., R. Coelho, A. C. Nunes, P. Andrade, L. Malheiro, and G. Macedo. "A rare complication of acute severe ulcerative colitis." Acta Gastro Enterologica Belgica 84, no. 3 (September 2021): 525–26. http://dx.doi.org/10.51821/84.2.022.
Abstract:
A 21-year-old female with ulcerative colitis presented with abdominal pain and bloody diarrhea. Laboratory studies revealed markedly elevated C-reactive protein and thrombocytosis. Flexible sigmoidoscopy revealed severe endoscopic activity with ulceration and spontaneous bleeding along rectum and sigmoid colon. Ulcerative colitis had been diagnosed 3 years before, presenting as severe and extensive disease (pancolitis). She had previously failed therapy with infliximab and vedolizumab and had recently started induction therapy with golimumab. She responded well to intravenous corticosteroids but, when switched to oral corticosteroids, there was symptomatic recurrence. Intravenous corticosteroids were re-started and she was evaluated for surgery. At this time, she developed new-onset tachycardia. Electrocardiogram revealed sinus tachycardia with heart rate of approximately 120 bpm. Because tachycardia could result from worsening colitis with potential serious complications, abdominal computerized tomography scan was performed and demonstrated mild lumen dilation and wall thickening consistent with acute colitis without evidence of pneumoperitoneum or toxic megacolon. Surprisingly, thoracic planes revealed the presence of free air dissecting mediastinal space (Figure 1). What is your diagnosis?
20
King, William, Raymond Richhart, David Hernandez Gonzalo, and Ellen Zimmerman. "Cytomegaloviral colitis in primary CMV viraemia in a young immunocompetent adult." BMJ Case Reports 15, no. 10 (October 2022): e249891. http://dx.doi.org/10.1136/bcr-2022-249891.
Abstract:
A man in his 20s presented with a 2-week history of fever, fatigue and diarrhoea. On arrival to the emergency department, he had clinical findings of sepsis. The care team initially suspected sepsis secondary to bacterial colitis and administered antibiotics. Further workup including a stool PCR assay for gastrointestinal pathogens failed to establish a diagnosis, and he had no evidence of immune compromise. Colonoscopy revealed mucosal ulceration presumed to be ulcerative colitis. Histopathology obtained after discharge revealed severe colitis with cytomegalovirus (CMV) inclusions. Serological studies indicated a primary CMV infection. To our knowledge, this is the first report of a primary CMV infection presenting as severe colitis and systemic disease in a young immunocompetent patient without underlying disease.
21
Tan, C. X. W. "Oral manifestations of ulcerative colitis." Nederlands Tijdschrift voor Tandheelkunde 124, no. 05 (May 5, 2017): 243–47. http://dx.doi.org/10.5177/ntvt.2017.05.16217.
22
Asrafiel, Hana M., Eda M. A. Alshailabi, Fatimah A. Mohammed, and Ahmed S. H. Ahmeedah. "Histopathological evaluation of ulcerative colitis induced by white vinegar in albino rats." Al-Kitab Journal for Pure Sciences 8, no. 02 (June 9, 2024): 23–30. http://dx.doi.org/10.32441/kjps.08.02.p3.
Abstract:
The ulcerative colitis (UC) is an inflammatory bowel illness which causes persistent inflammation of the colon's innermost layers. A prominent characteristic of ulcerative colitis (UC) is the stool's blood and mucous contents. This study determined to investigate the effects of white vinegar (WV) on colon tissues in rats. Two groups of twenty rats were created; the primary group was a control, healthy group, and the WV was administered to the second group at a dose of [1 ml/kg (5%)] via orally gavage for two weeks. Findings revealed the emergence of histopathological alterations like mucosal erosions, ulceration, loss of normal architecture, mucosal atrophy, and hemorrhage; numerous crypts have inflammatory cells that entered them, blood vessels are dilated and oedema, the serosa is destroyed, which demonstrates the devastation of the mucosal lining destruction with goblet cell hyperplasia, focal necrosis of epithelium with demolished connective tissues, accumulation of inflammatory cells in the mucosa, lamina propria, and muscularis mucosa, as well as submucosal oedema when compared with the control rats. The PAS-reaction histochemical analysis showed that the treated rats had lower levels of carbohydrates than the control animals. The findings of the study demonstrated that white vinegar was a dangerous substance linked to histological alterations that resulted in acute ulcerative colitis when used daily for two weeks.
23
Hanauer, Stephen B. "Potential Human Models of Infammatory Bowel Disease." Canadian Journal of Gastroenterology 9, no. 6 (1995): 316–18. http://dx.doi.org/10.1155/1995/284725.
Abstract:
Similar to animal models of inflammatory bowel disease (IBD), there is no single human model representative of ulcerative colitis or Crohn's disease. An optimal human model awaits etiopathogenetic definitions and further reclassification or depiction of clinicopathological scenarios. Current human models can be classified into models depicting risk of disease; preclinical disease; acute inflammation; and miscellaneous IBD. Family studies are the best means of pursuing patients at risk. Evolving genetic and serological markers may further identify subgroups to assess with permeability probes, leukocyte scans or endoscopy for preclinical disease. Provocation with nonsteroidal anti-inflammatory drugs (NSAIDs) may be useful in selected patients because NSAID mucosal damage may induce or mimic IBD. Alternative natural history or interventional studies in patients with human leukocyte antigen (HLA)-B27 spondylarthropathy may be useful. The disease margin and pouchitis are models within the disease state of ulcerative colitis as are the aphthous ulcer, anastomotic margin and diverted fecal stream for Crohn's disease. Newly defined colitides, such as microscopic and collagenous colitis and diversion colitis, also provide potential comparative models to evaluate mucosal immune, inflammatory, reparative, secretory and absorptive regulation.
24
Green, Nicole, Dale Lee, Ghassan Wahbeh, and M. Cristina Pacheco. "Do Histologic Features Help Predict Colectomy in Pediatric Patients Presenting With Acute Severe Colitis?" Pediatric and Developmental Pathology 23, no. 5 (June 8, 2020): 380–86. http://dx.doi.org/10.1177/1093526620929477.
Abstract:
Background Multiple prior studies have looked at clinical and laboratory parameters in ulcerative colitis to predict prognosis, but individual histologic features of inflammation and their prognostic significance have not been well studied. The purpose of our study was to determine whether histologic features at presentation with acute severe colitis predict colectomy in pediatric patients. Methods Patients were identified retrospectively through the gastroenterology and pathology databases. Demographic information, duration of disease, laboratory data, endoscopic appearance at scope, and histologic features of inflammation were reviewed along with medical therapies. Patients who underwent surgery within 90 days of hospitalization were compared to those who did not. Results Fifty patients with acute severe colitis, defined as Pediatric Ulcerative Colitis Activity Index ≥65, were included. Sixteen patients had colectomies performed within 90 days of presentation. No statistically significant difference was found between the surgery and no-surgery groups for patient age, albumin, hemoglobin, or C-reactive protein, though hemoglobin trended toward significance, P = .05. The endoscopic Mayo score and histologic features of inflammation (architectural changes, chronic inflammation, eosinophils, neutrophils within the lamina propria, neutrophils in epithelium, crypt destruction, and ulceration) were similar between groups. Conclusion In pediatric patients presenting for hospitalization with acute severe colitis, no histologic features of inflammation predicted colectomy within 90 days.
25
Alese, Olatunji B., and David O. Irabor. "Pyoderma gangrenosum and ulcerative colitis in the tropics." Revista da Sociedade Brasileira de Medicina Tropical 41, no. 6 (December 2008): 664–67. http://dx.doi.org/10.1590/s0037-86822008000600020.
Abstract:
Pyoderma gangrenosum is a rare inflammatory skin condition, characterized by progressive and recurrent skin ulceration. There may be rapidly enlarging, painful ulcers with undermined edges and a necrotic, hemorrhagic base. Disorders classically associated with pyoderma gangrenosum include rheumatoid arthritis, inflammatory bowel disease, paraproteinemia and myeloproliferative disorders. There have been some reports of the occurrence of pyoderma gangrenosum in Africa, and in Nigeria, but only one specifically reported pyoderma gangrenosum in association with ulcerative colitis. We report on a 45-year-old man who presented with pyoderma gangrenosum associated with ulcerative colitis; the second report in Nigeria. The skin lesions were managed with daily honey wound dressings. Oral dapsone and prednisolone were started. The frequency of the bloody diarrhea decreased, and was completely resolved by the second week after admission. The ulcers also showed accelerated healing. The goal of therapy is directed towards the associated systemic disorder, if present.
26
Lutsyk, A. P., and E. I. Shorikov. "Diagnostic Value of Clinical and Laboratory Parameters in the Diagnosis of Non-Specific Ulcer Colitis." Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 5, no. 6 (December 12, 2020): 136–40. http://dx.doi.org/10.26693/jmbs05.06.136.
Abstract:
The etiology of ulcerative colitis is still unknown. The number of works dealing with a comprehensive assessment of the role of clinical, laboratory, endoscopic, as well as immunological and genetic factors in the formation of unfavorable forms of ulcerative colitis is extremely small, and their results seem ambiguous. The purpose of the study was to determine the diagnostic value of clinical and laboratory signs in relation to verification of the depth of endoscopic lesion in patients with ulcerative colitis. Material and methods. 68 patients with ulcerative colitis (36 men and 32 women) were examined. The average age was 38.0±4.5 years. All patients were inspected with colonoscopy. Clinical, laboratory, immunological research, as well as computed tomography were carried out. Disease activity was determined according to the Truelove-Witts classification. Results and discussion. The obtained results showed that all intestinal symptoms (stool frequency more than 4 times a day, abdominal pain, tenesmus, hematochezia) had a reliable diagnostic value (р<0.05) in the presence of contact vulnerability and ulceration of the intestinal mucosa. The greatest sensitivity was characteristic of abdominal pain (94.1 [84.1-96.3]). It was found that the diagnostic sensitivity of tachycardia and uveitis is unreliable. Among the clinical indicators, the greatest diagnostic value was established for anemic syndrome (p<0.05), among additional signs was for sclerosing cholangitis (p<0.05). With regard to laboratory parameters, the diagnostic value was proven for hemoglobin levels <90 g/l (p<0.05) and hypoproteinemia (p<0.05). The diagnostic concentration of C-reactive protein for predicting a mucosal defect was determined at a level of more than 10 mg/L in terms of sensitivity and specificity (p<0.05). The level of fecal calprotectin more than 200 μg/g (p<0.05) was highly sensitive and highly specific. Conclusion. The study showed the possibilities of computed tomography for verifying of ulcerative defects. The method is highly sensitive in ulcerative colitis (sensitivity is 95.6 [85.9-97.1], specificity is (96.7 [83.3-99.4]), with a low probability of false-negative and false-positive results (p<0.05)
27
Khan, Imran Anwar, Sadaf Yousaf, Touseef Anwar, Muhammad Rashid Ali, Muhammad Sarfraz, and Aftab Mohsin. "Characteristics and associations of Ulcerative colitis in Pakistani population." Professional Medical Journal 27, no. 05 (May 10, 2020): 1079–84. http://dx.doi.org/10.29309/tpmj/2020.27.05.4446.
Abstract:
Objectives: To determine the prevalence of ulcerative colitis, extent and associations of disease with age, gender, indication of the procedure and coexisting disorders in patients who underwent sigmoidoscopy at Liver Clinic, Lahore, Pakistan. Study Design: Retrospective study. Setting: Liver Clinic, Lahore. Period: February 2010 to July 2017. Material & Methods: Group of ulcerative colitis patients was compared with group without ulcerative colitis among who underwent sigmoidoscop y from genders, age groups, indication for sigmoidoscopy, and presence of ulcerative colitis were the qualitative variables, while age of the patients was the only quantitative variable. Data was analysed on SPSS-25was used. Means with standard deviations were computed of quantitative variables, and frequencies-percentages for qualitative variables. Chi-square test for independence and Independent sample T test were used for qualitative and quantitative variables respectively to determine their significant association with presence of ulcerative colitis. The p values were taken statistically significant if < 0.05. Results: Out of total of 998 patients who underwent sigmoidoscopy, 115 (11.52%) had ulcerative colitis. The mean age of ulcerative colitis patients was 37.87 + 14.23 years while mean age of patients not suffering ulcerative colitis was 44.42 + 15.29 years. Among ulcerative colitis suffering cohort, 6.1% were children, 41.7% young adults, 44.3% middle aged adults and 7.8% were older adults. Out of 115 patients, 22 (19.1%) had ulcerative proctitis, 25 (21.7%) ulcerative proctosigmoiditis and in remaining 68 (59.1%) patients had colitis throughout visualized tract. 29 (25.2%) ulcerative colitis patients had supplementary associated disorders: 11 (37.9%) had superimposed pseudomembranous colitis, 8 (27.6%) had pseudopolyps formation, 7 (24.1%) had solitary benign polyps, 2 (6.9%) had internal hemorrhoids and 1 (3.4%) had malignant growth as well. The ulcerative colitis was more prevalent in female gender (p<0.01), younger age group (p<0.01) and where bloody diarrhea was presenting complaint (p<0.01). Conclusion: Ulcerative colitis is prevalent in all age groups and female gender is more affected in our population. Majority patients have disease not limited to only rectum and sigmoid colon, rather possess aggressive disease pattern associated with more risks and hazards. Ulcerative colitis usually presents with bloody diarrhea in our people. There are multiple coexisting disorders, where higher prevalence of pseudomembranous colitis in ulcerative colitisdemands avoidance of undue antibiotics and better hygiene.
28
GHIDERSA, Andreea, Ruxandra BABIUC, and Lucian NEGREANU. "Case Presentation: a Facial Ulceration in a Patient with Ulcerative Colitis." Medicina Moderna - Modern Medicine 27, no. 3 (September 26, 2020): 245–47. http://dx.doi.org/10.31689/rmm.2020.27.3.245.
Abstract:
We present the case of a patient with severe ulcerative colitis treated with infliximab that was admitted for an extensive facial ulceration located on the left cheek. Pyoderma gangrenosum, bacterial, mycobacterial and fungal infection were taken into account. The patient was diagnosed with a Klebsiella abscess originating from a tooth infection. Infectious complications might arise more frequently in IBD patients treated with anti TNF and adequate diagnosis and therapy is required.
29
Escoté, Xavier. "Potential clinical treatment of colitis with cardiotrophin-1." Clinical Science 132, no. 20 (October 19, 2018): 2169–74. http://dx.doi.org/10.1042/cs20171626.
Abstract:
In a recent issue of Clinical Science, Prieto-Vicente et al. [Clin. Sci. (2018) 132, 985–1001] have smartly demonstrated a potential new use of cardiotrophin-1 (CT-1) to treat and palliate an inflammatory bowel disease such as ulcerative colitis. In that work, authors report that in ulcerative colitic mice, administration of exogenous recombinant CT-1 (rCT-1) promotes lower colon damage and lower disease activity index, reducing systemic levels of tumor necrosis factor α (TNF-α) and also diminishing TNF-α expression in colon together with the reduction in other common inflammation markers. Besides, in vivo rCT-1 administration induces activation of several molecular pathways, including nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription (STAT)-3, and abolishes bacterial translocation from intestine to other organs, including mesenteric ganglia, lungs, and spleen. Additionally, these results were nicely corroborated in CT-1 depleted mice; in which colon damage and ulcerative colitis severity were greater compared with the wild-type counterparts. All together, these results suggested that CT-1 could be a promising new therapeutic approach for treating inflammatory bowel disease, particularly ulcerative colitis. However, further studies are required to determine its major mechanisms of action and the potential efficacy of CT-1 in human inflammatory bowel diseases.
30
NISHIKAWA, Alvaro Mitsunori, Luciano PALADINI, Régis DELFINI, Paulo Gustavo KOTZE, and Otavio CLARK. "DECISION TREE CONSTRUCTION AND COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ULCERATIVE COLITIS WITH PENTASA®MESALAZINE 2 G SACHET." Arquivos de Gastroenterologia 50, no. 4 (December 2013): 297–303. http://dx.doi.org/10.1590/s0004-28032013000400011.
Abstract:
ContextUnspecified Ulcerative Rectocolitis is a chronic disease that affects between 0.5 and 24.5/105 inhabitants in the world. National and international clinical guidelines recommend the use of aminosalicylates (including mesalazine) as first-line therapy for induction of remission of unspecified ulcerative rectocolitis, and recommend the maintenance of these agents after remission is achieved. However, multiple daily doses required for the maintenance of disease remission compromise compliance with treatment, which is very low (between 45% and 65%). Use of mesalazina in granules (2 g sachet) once daily - Pentasa® sachets 2 g - can enhance treatment adherence, reflecting in an improvement in patients' outcomes.ObjectiveTo evaluate the evidence on the use of mesalazine for the maintenance of remission in patients with unspecified ulcerative rectocolitis and its effectiveness when taken once versus more than once a day. From an economic standpoint, to analyze the impact of the adoption of this dosage in Brazil's public health system, considering patients' adherence to treatment.MethodsA decision tree was developed based on the Clinical Protocol and Therapeutic Guidelines for Ulcerative Colitis, published by the Ministry of Health in the lobby SAS/MS n° 861 of November 4 th, 2002 and on the algorithms published by the Associação Brasileira de Colite Ulcerativa e Doença de Crohn, aiming to get the cost-effectiveness of mesalazine once daily in granules compared with mesalazine twice daily in tablets.ResultsThe use of mesalazine increases the chances of remission induction and maintenance when compared to placebo, and higher doses are associated with greater chance of success without increasing the risk of adverse events.ConclusionThe use of a single daily dose in the maintenance of remission is effective and related to higher patient compliance when compared to the multiple daily dose regimens, with lower costs.
31
Wibowo, Agung Ary, Hendy Buana Vijaya, Didik Dwi Sanyoto, Hendra Sutapa, Husna Dharma Putera, and Kenanga Marwan Sikumbang. "Mayo Endoscopic Score (MES) as a reference for the histological active disease of ulcerative colitis." Bali Medical Journal 12, no. 1 (January 19, 2023): 340–44. http://dx.doi.org/10.15562/bmj.v12i1.3766.
Abstract:
Background: The degree of inflammation dramatically affects the morbidity of ulcerative colitis. Local and systemic inflammation features are modalities to determine disease severity and evaluation. Furthermore, local inflammation can be seen from endoscopic and histological examinations. This study aimed to examine the relationship of histological inflammatory profile with endoscopic scoring in ulcerative colitis patients. Method: A retrospective study was conducted using colonoscopic and histologic data from 68 ulcerative colitis patients. The endoscopic grade was assessed based on the Mayo Endoscopic Score (MES). The histological grade was analyzed using a microscope by assessing acute and chronic inflammatory cells and the presence of ulceration and crypt changes based on the Nancy Score Index and Geboes Score Index. Furthermore, the analysis test used Spearman and Mann-Whitney. Results: There is a significant positive relationship between endoscopic and histology scoring. The Nancy Score Index and MES combination yields 95% CI: 0.000-0.043, p=0.000, Correlation coefficient (r)=0.810, and odds ratio (OR)=3.272. Meanwhile, the combination of the Geboes Score Index with MES yields 95% CI: 0.000-0.043; p=0.000; r=0.727; and OR=1.347. In each histological scoring, there was a significant difference between the Nancy Score Index and Geboes Score Index tα (r = 0.018; p<0.05). Conclusion: There is a significant relationship between histological and endoscopic scoring. Therefore, an endoscopic examination can be a reference for histologically active disease.
32
Reinisch, W., K.-H. Heider, G. Oberhuber, C. Dejaco, M. Müllner, G. R. Adolf, and C. Gasché. "Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn’s disease." Gut 43, no. 3 (September 1, 1998): 375–82. http://dx.doi.org/10.1136/gut.43.3.375.
Abstract:
Background—Increased expression of CD44v6 on colonic crypt epithelial cells in ulcerative colitis has been suggested as a diagnostic tool to distinguish ulcerative colitis from colonic Crohn’s disease.Aims—To investigate colonic CD44v6 expression and serum concentrations of soluble CD44v6 (sCD44v6) in patients with ulcerative colitis and Crohn’s disease.Methods—Colonic biopsy samples were obtained from 16 patients with ulcerative colitis, 13 with ileocolonic Crohn’s disease, and 10 undergoing polypectomy. Serum samples were obtained from 15 patients with active ulcerative colitis, 20 with active Crohn’s disease, and 20 healthy donors. Colonic CD44v6 expression was evaluated immunohistochemically by monoclonal antibody 2F10 and the higher affinity monoclonal antibody VFF18. Serum sCD44v6 concentrations were measured by ELISA.Results—2F10 stained colonic epithelium of inflamed ulcerative colitis and Crohn’s disease samples in 80% and 40% of cases, respectively, and VFF18 in 95% and 87%, respectively. Both monoclonal antibodies displayed a sensitivity and specificity of 60% and 87% to differentiate ulcerative colitis from colonic Crohn’s disease. Serum concentrations of sCD44v6 were lower in patients with ulcerative colitis (median 153 ng/ml; interquartile range (IQR) 122–211) compared with Crohn’s disease (219; IQR 180–243) and healthy donors (221; IQR 197–241 (p=0.002)). Its sensitivity and specificity to discriminate ulcerative colitis from Crohn’s disease was 75% and 71%, respectively.Conclusion—Colonic CD44v6 and serum sCD44v6 concentrations do not facilitate reliable differential diagnosis between ulcerative colitis and Crohn’s disease.
33
Roy, Kayla, Edward Moncada, and Lavanya Reddivari. "THE ONSET AND SEVERITY OF ULCERATIVE COLITIS IN IL-10 -/- MICE IS NOT DEPENDENT ON FECAL MICROBIOTA TRANSPLANTATION FROM ULCERATIVE COLITIS PATIENTS." Inflammatory Bowel Diseases 29, Supplement_1 (January 26, 2023): S50. http://dx.doi.org/10.1093/ibd/izac247.098.
Abstract:
Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects around 1% of the U.S population. IBD is comprised of Chron’s Disease and Ulcerative Colitis (UC), with UC having a higher incidence rate. IBD is believed to be caused by immune dysfunction and several environmental factors. Specifically in UC, bacterial dysbiosis is positively correlated with colitis severity and incidence. Thus, we propose that genetically susceptible mice colonized with human colitis-associated bacteria will exhibit early onset and increased colitis severity compared to mice colonized with fecal microbiota from healthy individuals. To test this hypothesis, germ-free IL-10-/- mice of an average age of 20 weeks were gavaged orally with fecal samples from healthy individuals and a severe colitis patient with a fecal calprotectin level of 1947 ug/mg. The Disease Activity Index (DAI) was calculated based on occult blood, weight loss, stool consistency, and grimace. DAI was used to assess colitis severity weekly in transplanted mice for eight weeks.16S rRNA sequencing analysis showed a significant difference in alpha (Shannon Index) and beta diversity (unweighted UniFrac) between the colitis patient and healthy donors indicating dysbiosis (p=.0001; p=.001). The colitis donor had a reduction in species richness. Furthermore, recipient mice clustered with the donors in their bacterial composition. Compared to mice with healthy individual-associated bacteria, colitic-associated bacteria did not significantly increase the colitis incidence or severity in IL-10 -/- mice. Furthermore, there were no significant differences in DAI scores, organ weights, and gut permeability between the treatments. Thus, this study demonstrates that bacterial dysbiosis alone is not sufficient to induce colitis in genetically predisposed mice.
34
Murtiningrum, Fitria Senja, and Deni Noviana. "Colonoscopy to diagnose chronic ulcerative colitis in an 11-years-old Maltese." ARSHI Veterinary Letters 4, no. 1 (March 6, 2020): 1–2. http://dx.doi.org/10.29244/avl.4.1.1-2.
Abstract:
An 11-year-old castrated male Maltese was examined for increased frequency of defecation, mucus in feces, and chronic diarrhea with hematochezia. The dog was referred to Veterinary Teaching Hospital, Faculty of Veterinary Medicine, IPB University for further evaluation. Ultrasonography and colonoscopy were performed to further diagnose. Abdominal ultrasonography was taken using a linear probe with frequency 6-11 MHz. Colonoscopy was performed using colonoscope with tube length 700 mm and diameters 10 mm under anesthesia. Abdominal ultrasonography showed that the dog had a mucocele gall bladder, cholecystitis, hepatitis, slight-mild splenitis, nephrolithiasis, urolithiasis and thickened of the duodenal wall due to inflammatory bowel diseases. Colonoscopy showed ulceration and hemorrhage along the surface of the colon, whereas hyperemia only seen on the ascending colon. Based on endoscopic examination, the dog was diagnosed with severe and chronic ulcerative colitis. The authors recommended that the colonic biopsy should be undertaken in the dog presented with chronic ulcerative colitis.
35
Javaid, Faraza, Naveed Aslam, Hafiza Maida Arshad, Ambreen Mehmood Awan, Wafa Majeed, and Qaiser Jabeen. "Gisekia pharnaceoides Restores Colonic Mucosal Homeostasis by Regulating Antioxidant Enzyme System and Cytokines Signaling in Ulcerative Colitis Mice Model." Endocrine, Metabolic & Immune Disorders - Drug Targets 22, no. 1 (January 2022): 133–42. http://dx.doi.org/10.2174/1871530321666211109151737.
Abstract:
Background: Gisekia pharnaceoides Linn. (Aizoaceae), traditionally known as baluka saag or sareli is commonly found in the deep Cholistan region of Pakistan. It is used by native community for the mitigation of a range of diseases, including inflammatory disorders and gastric ulcers. Objective: This study is designed to evaluate the defensive impact of G. pharnaceoides in acetic acid-induced ulcerative colitis in mice and to discover the mechanism for anti-inflammatory action. Method: The ethanolic crude extract of G. pharnaceoides (Gp.Cr) was prepared and evaluated for phytochemical substances by preliminary screening and HPLC analysis. Anti-inflammatory activity of Gp.Cr (300 and 500 mg/kg) was examined by administration of 200 µl of 7.5% acetic acid intra-rectally to induce ulcerative colitis and colonic mucosal injury, while mucosal homeostasis was evaluated by disease activity index, colonic ulcer score and hematological parameters. Anti-inflammatory potential was quantified by assessing antioxidant enzymes (SOD, CAT, GPX-1), lipid peroxides, nitric oxide and cytokines (IL-1β, IL-6, TNF-α) immunoassays and further analyzed by histological analysis of colon tissues. Results: Phytochemical screening of Gp.Cr revealed the presence of alkaloids, phenols, flavonoids, steroids, tannins and saponins, while HPLC analysis confirmed the presence of quercetin, gallic acid, coumaric and sinapic acid. In acetic acid-induced ulcerative colitis model, Gp.Cr (300 and 500 mg/kg) along with sulphasalazine (500 mg/kg) decreased disease activity index, ulcer scores and hematological parameters. Gp.Cr showed a significant anti-inflammatory potential by increasing antioxidant enzymes and decreasing lipid peroxides, nitric oxide and cytokines levels. Histopathological examination showed significant decline in ulceration and tissue disruption. Conclusion: Hence, the findings confirmed the effectiveness of G. pharnaceoides crude extract in the treatment of ulcerative colitis and might be a promising remedy to manage inflammatory disorders.
36
Steiner, Annemarie, Thomas Reygaerts, Alessandra Pontillo, Isabella Ceccherini, Jonas Moecking, Fiona Moghaddas, Sophia Davidson, et al. "Recessive NLRC4-Autoinflammatory Disease Reveals an Ulcerative Colitis Locus." Journal of Clinical Immunology 42, no. 2 (November 16, 2021): 325–35. http://dx.doi.org/10.1007/s10875-021-01175-4.
Abstract:
Abstract Purpose NLRC4-associated autoinflammatory disease (NLRC4-AID) is an autosomal dominant condition presenting with a range of clinical manifestations which can include macrophage activation syndrome (MAS) and severe enterocolitis. We now report the first homozygous mutation in NLRC4 (c.478G > A, p.A160T) causing autoinflammatory disease with immune dysregulation and find that heterozygous carriers in the general population are at increased risk of developing ulcerative colitis. Methods Circulating immune cells and inflammatory markers were profiled and historical clinical data interrogated. DNA was extracted and sequenced using standard procedures. Inflammasome activation assays for ASC speck formation, pyroptosis, and IL-1β/IL-18 secretion confirmed pathogenicity of the mutation in vitro. Genome-wide association of NLRC4 (A160T) with ulcerative colitis was examined using data from the IBD exomes portal. Results A 60-year-old Brazilian female patient was evaluated for recurrent episodes of systemic inflammation from six months of age. Episodes were characterized by recurrent low-grade fever, chills, oral ulceration, uveitis, arthralgia, and abdominal pain, followed by diarrhea with mucus and variable skin rash. High doses of corticosteroids were somewhat effective in controlling disease and anti-IL-1β therapy partially controlled symptoms. While on treatment, serum IL-1β and IL-18 levels remained elevated. Genetic investigations identified a homozygous mutation in NLRC4 (A160T), inherited in a recessive fashion. Increased ASC speck formation and IL-1β/IL-18 secretion confirmed pathogenicity when NLRC4 (A160T) was analyzed in human cell lines. This allele is significantly enriched in patients with ulcerative colitis: OR 2.546 (95% 1.778–3.644), P = 0.01305. Conclusion NLRC4 (A160T) can either cause recessively inherited autoinflammation and immune dysregulation, or function as a heterozygous risk factor for the development of ulcerative colitis.
37
Ravi Dabas, Dixit V K, and Kar A C. "Critical Review of Raktatisara vis-a-vis Ulcerative Colitis." International Journal of Research in Pharmaceutical Sciences 12, no. 2 (April 7, 2021): 999–1002. http://dx.doi.org/10.26452/ijrps.v12i2.4616.
Abstract:
Many studies have been conducted for the role of Ahara (~dietary habits), Vihara (~abnormal Physical activity) and Manas (~Psychological factors) and their association with pathogenesis of Ulcerative colitis, which is a subtype of inflammatory bowel disease, which pursue a protracted relapsing and remitting course, usually extending over years. The causes of relapsing of ulcerative colitis are not known. Dietary factors have been associated in the pathogenesis of ulcerative colitis as well as associated with an increased risk of relapse of ulcerative colitis. Here, we have reviewed the probable mechanisms of the role of diet and its association with pathogenesis of Ulcerative colitis (UC). In Ayurveda, on the basis of signs and symptoms ulcerative colitis can be best compared with Raktatisara. This article is an attempt to do critical review and put a light on the role of diet, faulty lifestyle and Psychological factors in occurrence and progression of Ulcerative colitis (UC), and try to explain Etiopathogenesis of Raktatisara in relation to ulcerative colitis by going through Ayurvedic texts, Google Scholar, PubMed journals etc.
38
Lugonja, Sofija I., Ivana L. Pantic, Tamara M. Milovanovic, Vesna M. Grbovic, Bojana M. Djokovic, Željko D. Todorovic, Stefan M. Simovic, Raša H. Medovic, Nebojsa D. Zdravkovic, and Natasa D. Zdravkovic. "Atherosclerotic Cardiovascular Disease in Inflammatory Bowel Disease: The Role of Chronic Inflammation and Platelet Aggregation." Medicina 59, no. 3 (March 11, 2023): 554. http://dx.doi.org/10.3390/medicina59030554.
Abstract:
Background and Objectives: Atherosclerosis is one of inflammatory bowel disease’s most significant cardiovascular manifestations. This research aimed to examine the relationship between biochemical, haemostatic, and immune parameters of atherosclerosis and ulcerative colitis patients and its relationship to platelet aggregation. Materials and Methods: A clinical, observational cross-sectional study was performed, during which the tested parameters were compared in the experimental and control groups. The patients were divided into four groups. The first group had 25 patients who had ulcerative colitis and atherosclerosis. The second group included 39 patients with ulcerative colitis without atherosclerosis. The third group comprised 31 patients suffering from atherosclerosis without ulcerative colitis, and the fourth group comprised 25 healthy subjects. Results: In our study, we registered statistically higher levels of inflammatory markers like SE, CRP, Le, fecal calprotectin, TNF-α, and IL-6, as well as the higher value of thrombocytes and thrombocyte aggregation in the group of patients with ulcerative colitis compared to the control group. Lower levels of total cholesterol and LDL were also recorded in patients with ulcerative colitis and atherosclerosis and ulcerative colitis without atherosclerosis compared to healthy control. Triglyceride and remnant cholesterol were higher in patients with ulcerative colitis and atherosclerosis when compared to patients with ulcerative colitis and healthy control but lower than in patients with atherosclerosis only. Conclusions: Several inflammatory markers and platelet aggregation could be good discrimination markers for subjects with ulcerative colitis with the highest risk of atherosclerosis.
39
Ainley, C. C., J. Cason, L. K. Carlsson, B. M. Slavin, and R. P. H. Thompson. "Zinc status in inflammatory bowel disease." Clinical Science 75, no. 3 (September 1, 1988): 277–83. http://dx.doi.org/10.1042/cs0750277.
Abstract:
1. The zinc contents of plasma, erythrocytes, polymorphonuclear leucocytes and mononuclear leucocytes from 18 normal control subjects, 31 patients with Crohn's disease and 15 patients with ulcerative colitis were measured. 2. Plasma zinc levels were low in Crohn's disease, particularly in malnourished patients, and related to plasma albumin concentrations, but were normal in ulcerative colitis. 3. Erythrocyte zinc levels were normal in both Crohn's disease and ulcerative colitis. 4. Mean polymorphonuclear leucocyte zinc levels were normal in Crohn‘s disease and ulcerative colitis. Ten per cent of Crohn's disease patients had subnormal levels, which were associated with inactive disease, while 10% had elevated levels, which were associated with active disease. Seven per cent of ulcerative colitis patients had subnormal levels. Mononuclear leucocyte zinc levels were normal in Crohn's disease and in ulcerative colitis. 5. Tissue zinc depletion occurs in only a few patients with Crohn's disease and ulcerative colitis.
40
Yan, Pengguang, Yanan Wang, Xiangchen Meng, Hong Yang, Zhanju Liu, Jiaming Qian, Weixun Zhou, and Jingnan Li. "Whole Exome Sequencing of Ulcerative Colitis–associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients." Inflammatory Bowel Diseases 25, no. 8 (February 22, 2019): 1293–301. http://dx.doi.org/10.1093/ibd/izz020.
Abstract:
AbstractBackgroundCarcinogenesis is a severe consequence of chronic ulcerative colitis. We investigated the somatic mutations and pathway alterations in ulcerative colitis–associated colorectal cancer (CRC) in Chinese patients compared with sporadic CRCs to reveal potential therapeutic targets in ulcerative colitis–associated CRC.MethodsWhole exome sequencing was performed on archival tumor tissues and paired adjacent nondysplastic mucosa from 10 ulcerative colitis–associated CRC patients at a high risk of carcinogenesis. Genomic alteration profiles from 223 primary CRCs from The Cancer Genome Atlas served as sporadic CRC controls. A meta-analysis was performed to investigate differences in major genetic mutations between ulcerative colitis–associated and Crohn’s disease–associated CRCs.ResultsWe identified 44 nonsilent recurrent somatic mutations via whole exome sequencing, including 25 deleterious mutations involved in apoptosis and the PI3K-Akt pathway (COL6A3, FN1), autophagy (ULK1), cell adhesion (PODXL, PTPRT, ZFHX4), and epigenetic regulation (ARID1A, NCOR2, KMT2D, NCOA6, MECP2, SUPT6H). In total, 11 of the 25 mutated genes significantly differed between ulcerative colitis–associated CRC and sporadic CRC (APC, APOB, MECP2, NCOR2, NTRK2, PODXL, RABGAP1, SIK3, SUPT6H, ULK1, USP48). Somatic TP53 mutations occurred in 33% of ulcerative colitis–associated CRCs. Subsequent meta-analysis revealed distinct mutation profiles for Crohn’s disease– and ulcerative colitis–associated CRCs. Mutations involving the NF-kB pathway and epigenetic regulation were more common in ulcerative colitis–associated CRCs than in sporadic CRCs.ConclusionDistinct genomic alteration profiles of deleterious somatic mutations were found in ulcerative colitis–associated and sporadic CRCs. Mutations of epigenetic regulators, such as KMT2D and NCOA6, were common, suggesting an epigenetic pathomechanism for colitis-associated carcinoma in Chinese patients.
41
Flanagan, Paul, Barry J. Campbell, and Jonathan M. Rhodes. "Bacteria, good and bad: Host–microbiota interactions in inflammatory bowel disease." Biochemist 33, no. 4 (August 1, 2011): 22–25. http://dx.doi.org/10.1042/bio03304022.
Abstract:
Inflammatory bowel disease (IBD), a term encompassing the conditions ulcerative colitis (UC) and Crohn's disease, affects around 1 in 300 people in the UK and causes significant morbidity, although, thankfully, little mortality1. Although UC is limited to the colon and causes mucosal ulceration, Crohn's disease can affect any part of the intestine and causes ulceration, transmural inflammation, stricturing, fistula and abscess formation. Both are relapsing and remitting diseases and, despite advances in medical treatments, including immunosuppressants and drugs which specifically block pro-inflammatory molecules (tissue necrosis factor; TNF), about 25% with UC and 50–80% with Crohn's disease will require major surgery at least once in their lives.
42
Keshteli, Ammar Hassanzadeh, Karen L. Madsen, and Levinus A. Dieleman. "Diet in the Pathogenesis and Management of Ulcerative Colitis; A Review of Randomized Controlled Dietary Interventions." Nutrients 11, no. 7 (June 30, 2019): 1498. http://dx.doi.org/10.3390/nu11071498.
Abstract:
Epidemiological and experimental studies have suggested that diet is one of the environmental factors that contributes to the onset and pathophysiology of ulcerative colitis. Although many patients suffering from ulcerative colitis attribute their symptoms or disease relapse to dietary factors, only a few well-designed randomized controlled trials have been done to investigate the role of diet in the management of ulcerative colitis. Here, we review the potential mechanisms of the relationship between diet and pathogenesis of ulcerative colitis and summarize randomized controlled dietary interventions that have been conducted in ulcerative colitis patients.
43
Chen, Grant I., Fred Saibil, and Izabella Morava-Protzner. "Two for One: Coexisting Ulcerative Colitis and Crohn’s Disease." Canadian Journal of Gastroenterology 16, no. 1 (2002): 29–34. http://dx.doi.org/10.1155/2002/219187.
Abstract:
Three cases of coexisting ulcerative colitis and Crohn’s disease are presented. In the first case, the patient had a long-standing history of ulcerative proctitis before developing Crohn’s colitis. In the two remaining cases, the patients presented initially with Crohn’s disease of the ileum and, subsequent to resection, developed ulcerative colitis. Well-documented cases of patients diagnosed with both ulcerative colitis and Crohn’s disease are rare. The literature on such cases is reviewed, and the controversy over whether ulcerative colitis and Crohn’s disease are two distinct diseases is explored.
44
Panova, I. V., S. Kh Dombayan, and G. M. Letifov. "Regional features of the course of ulcerative colitis: clinical observations (on the example of Rostov-on-Don)." Terapevt (General Physician), no. 2 (January 28, 2022): 45–52. http://dx.doi.org/10.33920/med-12-2202-05.
Abstract:
The aim of the study was to identify the clinical, epidemiological and therapeutic features of ulcerative colitis in children in Rostov-on-Don. Under the observation were 34 children aged 1 to 14 years with a diagnosis of ulcerative colitis, which was based on anamnesis, clinical picture, laboratory results, and colonoscopy. The activity of ulcerative colitis was assessed taking into account the PUCAI index. To determine the reliability of the compared indicators (%), the χ2 criterion was used. Clinical and epidemiological studies have shown an increase in the incidence of ulcerative colitis in children in Rostov-on-Don over the past 10 years. In the clinic of ulcerative colitis, mild, erased forms of the course of the disease dominated, which determined the later diagnosis at the prehospital stage. There was a «rejuvenation» of the disease: ulcerative colitis was more often detected in the preschool group of children. The incidence of ulcerative colitis in boys was higher than in girls. In the treatment of mild and moderate forms of ulcerative colitis, the use of basic drugs is very effective, taking into account the principle of «step up».
45
Dhakhwa, R., HG Shrestha, and IL Acharya. "Histopathological evaluation of ulcerative colitis in colonoscopic biopsies." Journal of Pathology of Nepal 6, no. 11 (March 17, 2016): 932–36. http://dx.doi.org/10.3126/jpn.v6i11.15676.
Abstract:
Background: Histopathologic evaluation of colonoscopic mucosal biopsy remains one of the earliest modalities of investigation in patients clinically suspected of ulcerative colitis. Pathologists should be aware of classical histomorphological features to avoid misdiagnosis. The aim of the present study was to evaluate histopathologic features as well as to determine possible atypical presentation.Materials and Methods: Forty newly diagnosed cases of ulcerative colitis were included in the study. Colonoscopic biopsies taken from rectum as well as various areas of colon and ileum depending upon clinical extent of involvement were submitted for histopathological evaluation. Diagnosis of ulcerative colitis was made by correlating clinical, endoscopic and histopathologic findings.Results: Out of 47 cases suspected of ulcerative colitis, histopathologic features were consistent with Ulcerative colitis in 40 cases. Almost all cases (97.5%) showed diffuse active colitis. Cryptitis (100%), crypt abscesses (75%) and basal plasmacytosis (85%) along with crypt architectural abnormalities (75%) and goblet cell depletion (70%) were classical histological changes associated with ulcerative colitis in active phase. Atypical presentations noticed were focal active colitis (2.5%), backwash ileitis (2.5%), rectal sparing (2.5%) and skip areas (5%).Conclusion: Accurate diagnosis of ulcerative colitis requires elaborate knowledge of histopathologic features along with awareness of possible atypical presentation.
46
Lim, A. G., F. L. Langmead, R. M. Feakins, and D. S. Rampton. "Diversion colitis: a trigger for ulcerative colitis in the in-stream colon?" Gut 44, no. 2 (February 1, 1999): 279–82. http://dx.doi.org/10.1136/gut.44.2.279.
Abstract:
The aetiology of ulcerative colitis is unknown. Two patients without pre-existing inflammatory bowel disease in whom end colostomy for faecal incontinence was complicated by diversion colitis in the defunctioned rectosigmoid colon, are described. In both instances, colitis with the clinical, colonoscopic, and microscopic features of ulcerative colitis developed about a year later in the previously normal in-stream colon proximal to the colostomy. These cases suggest that diversion colitis may be a risk factor for ulcerative colitis in predisposed individuals and that ulcerative colitis can be triggered by anatomically discontinuous inflammation elsewhere in the large intestine.
47
Yang, Chunhua, Mingzhen Zhang, Junsik Sung, Lixin Wang, Yunjin Jung, and Didier Merlin. "Autologous Exosome Transfer: A New Personalised Treatment Concept to Prevent Colitis in a Murine Model." Journal of Crohn's and Colitis 14, no. 6 (November 9, 2019): 841–55. http://dx.doi.org/10.1093/ecco-jcc/jjz184.
Abstract:
Abstract Background and Aims Epigenetic information delivered by intestinal exosomes can be useful for diagnosing intestinal diseases, such as ulcerative colitis, but the therapeutic effects of intestinal exosomes have not been fully exploited. We herein developed an autologous exosome therapy that could treat intestinal disease without any risk of inducing a systemic immunological reaction. Methods Intestinal exosomes were isolated and purified from faeces by our newly developed multi-step sucrose gradient ultracentrifugation method. Lipopolysaccharide [LPS]-activated macrophages were employed to test the in vitro anti-inflammatory ability of intestinal exosomes. To evaluate the in vivo anti-inflammatory activity of our system, we gavaged dextran sulphate sodium [DSS]-induced colitic mice with their own healing phase intestinal exosomes. Results Mouse intestinal exosomes are round extracellular vesicles with a hydrodynamic diameter of ~140 [±20] nm and a surface charge of ~-12 [±3] mV. Among the exosomes obtained at four different stages of DSS-induced ulcerative colitis [1, before treatment; 2, DSS-treated; 3, healing phase; and 4, back to normal], the healing phase exosomes showed the best in vitro anti-inflammatory effects and promotion of wound healing. Moreover, oral co-administration of autologous healing phase exosomes with DSS was found to significantly reduce the risk of a second round of DSS-induced ulcerative colitis in mice. Conclusions Intestinal exosomes obtained during the healing phase that follows induced intestinal inflammation could strongly promote wound healing in the host. Oral administration of autologous exosomes from the healing phase could be a safe and effective approach for treating the ulcerative colitis of a given patient in the context of personalised medicine.
48
Farhan Al-Rwi, Luay I., Maher M. Hassan Alakori, and Kifah H. Abdulghafour. "Prevalence of Entamoeba Histolytica infection in patients with colitis (Ulcerative and Infective)." Journal of the Faculty of Medicine Baghdad 58, no. 3 (October 2, 2016): 283–88. http://dx.doi.org/10.32007/jfacmedbagdad.583265.
Abstract:
Background: Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon that often extends to involve the remainder of the large intestine in a continuous manner. Intestinal amoebiasis can present as a chronic, dysenteric syndrome of diarrhea, weight loss, and abdominal pain that can last for years and mimic ulcerative colitis.Objective: Studying the prevalence of E..histolytica by using serological method ELISA for their detection, Investigate the possible role of E.histolytica as a cause of blood, diarrhea in non-ulcerative colitis group &Comparison between serological detection of E.histolytica and stool examination.Patients and Methods: Retrospective and prospective study was conducted on 48 patients (18 males, 30 females); 30 patients were diagnosed as ulcerative colitis and 18 as non ulcerative colitis patients by endoscopy, histopathology, radiology and laboratory examinations at Gastroenterology and Hepatology Teaching Hospital through the period between January 2008 and June 2008. From all patients and control, a detailed medical history was taken; routine examination and relevant investigations were done. Blood and fresh stool specimens were collected from all patients and control. General stool examination and ELISA tests for IgG anti E.histolytica antibodies were assessed. Results: Histological typing of ulcerative colitis grouped into chronic ulcerative colitis 42 cases(86.67%) and active on chronic ulcerative colitis 6 cases (13.33%). By general stool examination, E.histolytica was positive in (70%) of ulcerative colitis (53.33% cyst and 16.67% trophozoit) and results of ELISA test for IgG anti E.histolytica antibodies was significant compared with control group (P < 0.05). General stool examination and IgG anti- E histolytica antibodies has been found that 75.8% of patients have positive IgG and cyst stage, and 77.8% were have positive IgG and trophozoit stage , while 24.2% of negative GSE results were also negative for IgG anti-E.histolytica antibodies, and the association was significantcompared with control group (P < 0.05).Conclusion: E.histolytica IgG Abs were significantly higher in ulcerative colitis compared to non ulcerative colitis group .Close association between E.histolytica and ulcerative colitis also there is a high incidence of E.histolytica among group of non ulcerative colitis patients. Sensitivity of detection of E.histolytica by ELISA and GSE is rather equal.
49
Teplyuk, Nataliya P., Olga V. Grabovskaya, Diana T. Kusraeva, Ekaterina V. Grekova, Danila A. Koriakin, and Anastasia Yu Kostenko. "Successful treatment of pyoderma gangrenosum in a patient winh ulcerative colitis and COVID-19 infection: case report." Russian Journal of Skin and Venereal Diseases 25, no. 5 (January 11, 2023): 373–80. http://dx.doi.org/10.17816/dv111864.
Abstract:
Pyoderma gangrenosum is a rare inflammatory neutrophilic dermatosis, which causes ulceration of the skin. The condition is commonly associated with underlying systemic disorders such as inflammatory bowel disease, arthritis, and hematological disorders. Herein, we describe the case of a familiar association between pyoderma gangrenosum and ulcerative colitis complicated by the newly COVID-19 infection.
It is of particular clinical interest to address pyoderma gangrenosum lesions with concurrent treatment of associated disorders that may have influence on the course of the ulcer. Moreover, the therapy should cover as many diseases as possible while not being excessive to minimize possible side effects.
Thus, the selection of treatment that spans mutual pathophysiological features of all comorbidities represents the best option to make when handling pyoderma gangrenosum patients.
We present a case of the development of gangrenous pyoderma against the background of ulcerative colitis complicated by the new coronavirus infection COVID-19, which will raise awareness of gangrenous pyoderma as a relatively rare cause of ulcerative necrotic skin lesions, which can easily be confused with an infectious process.
Of particular clinical importance in the conditions of the COVID-19 pandemic is the correct treatment of gangrenous pyoderma. Only an integrated approach can give a positive result from the therapy.
50
Busingye, Doreen, Allan Pollack, and Kendal Chidwick. "Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study." PLOS ONE 16, no. 5 (May 27, 2021): e0252458. http://dx.doi.org/10.1371/journal.pone.0252458.
Abstract:
The burden of inflammatory bowel disease (IBD) in Australia is increasing but national data about the current prevalence are limited. We aimed to estimate the prevalence of IBD (including Crohn’s disease, ulcerative colitis and unspecified IBD) as well as Crohn’s disease and ulcerative colitis separately in a general practice population in Australia. We also assessed risk factors associated with Crohn’s disease and ulcerative colitis. We conducted a cross-sectional study using data from MedicineInsight, a national database of general practice electronic health records, from 1 July 2017 to 30 June 2019. The prevalence of IBD was calculated and stratified by sociodemographic characteristics. Logistic regression analysis was conducted to assess risk factors associated with Crohn’s disease and ulcerative colitis. The study comprised 2,428,461 regular patients from 481 practices. The estimated crude prevalence of IBD was 653 per 100,000 patients; Crohn’s disease was 306 per 100,000 and ulcerative colitis was 334 per 100,000. Males were independently associated with a lower risk of Crohn’s disease (OR: 0.86; 95% CI: 0.81, 0.90) but a greater risk of ulcerative colitis (OR: 1.12; 95% CI: 1.06, 1.17) than females. Compared to non-smokers, patients who were current smokers were associated with a greater risk of Crohn’s disease (OR: 1.13; 95% CI: 1.04, 1.23) but a lower risk of ulcerative colitis (OR: 0.52; 95% CI: 0.47, 0.57). Other factors positively associated with both Crohn’s disease and ulcerative colitis were age (≥ 25 years), non-Indigenous status and socioeconomic advantage. Our findings provide a current estimate of the prevalence of IBD, Crohn’s disease and ulcerative colitis in a large national general practice population in Australia and an assessment of the factors associated with Crohn’s disease and ulcerative colitis. These data can assist in estimating the health burden and costs, and planning for health services.